BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:TAK-921 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of TAK-921\, from ClinicalTrials.gov estimat
 es.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06238843-11359@assetmemo.bio
DTSTAMP:20261121T004110Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:TAK-921: Phase 3 readout est. (NCT06238843)
DESCRIPTION:TAK-921\, phase 3.\nStudy: A Multicenter\, Phase 3 Study of IBI
 343 Monotherapy Versus Treatment of Investigator's Choice in Subjects With
  Previously Treated\, Claudin (CLDN) 18.2-positive\, HER2-negative\, Gastr
 ic or Gastroesophageal Junction Adenocarcinoma (G-HOPE-001)\nEstimated pri
 mary completion: 30 December 2026. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/tak-921#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT06238843
URL:https://assetmemo.bio/drug/tak-921#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06770439-11359@assetmemo.bio
DTSTAMP:20261121T004110Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:TAK-921: Phase 2 readout est. (NCT06770439)
DESCRIPTION:TAK-921\, phase 2.\nStudy: IBI343 Combined With Chemotherapy in
  Advanced Pancreatic Cancer\nEstimated primary completion: January 2027. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/tak-921#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT06770439
URL:https://assetmemo.bio/drug/tak-921#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05458219-11359@assetmemo.bio
DTSTAMP:20261121T004110Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:TAK-921: Phase 1 readout est. (NCT05458219)
DESCRIPTION:TAK-921\, phase 1.\nStudy: A First-in-human Study of IBI343 in 
 Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors\nEs
 timated primary completion: 30 June 2027. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/tak-921#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT05458219
URL:https://assetmemo.bio/drug/tak-921#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07692750-11359@assetmemo.bio
DTSTAMP:20261121T004110Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:TAK-921: Phase 1/2 readout est. (NCT07692750)
DESCRIPTION:TAK-921\, phase 1/2.\nStudy: IBI343 Combined With Chemotherapy 
 in Advanced Pancreatic Cancer\nEstimated primary completion: 30 June 2027.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/tak-921#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT07692750
URL:https://assetmemo.bio/drug/tak-921#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07066098-11359@assetmemo.bio
DTSTAMP:20261121T004110Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:TAK-921: Phase 3 readout est. (NCT07066098)
DESCRIPTION:TAK-921\, phase 3.\nStudy: A Multicenter Study of IBI343 Monoth
 erapy Versus Placebo in Subjects With Previously Treated\, Claudin (CLDN) 
 18.2-positive\, Pancreatic Cancer(G-HOPE-002)\nEstimated primary completio
 n: 30 June 2027. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/tak-
 921#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 07066098
URL:https://assetmemo.bio/drug/tak-921#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07025889-11359@assetmemo.bio
DTSTAMP:20261121T004110Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:TAK-921: Phase 1/2 readout est. (NCT07025889)
DESCRIPTION:TAK-921\, phase 1/2\, Gastric Cancer.\nStudy: IBI343 Combined W
 ith Sintilimab Plus Chemotherapy in Gastric Cancer\nEstimated primary comp
 letion: July 2027. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ta
 k-921#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT07025889
URL:https://assetmemo.bio/drug/tak-921#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07483554-11359@assetmemo.bio
DTSTAMP:20261121T004110Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:TAK-921: Phase 2 readout est. (NCT07483554)
DESCRIPTION:TAK-921\, phase 2.\nStudy: IBI343 in Combination Therapy for Ad
 vanced Malignant Solid Tumors\nEstimated primary completion: 31 March 2028
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/tak-921#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT07483554
URL:https://assetmemo.bio/drug/tak-921#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07415525-11359@assetmemo.bio
DTSTAMP:20261121T004110Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:TAK-921: Phase 2 readout est. (NCT07415525)
DESCRIPTION:TAK-921\, phase 2.\nStudy: IBI343 Combined With Chemotherapy as
  Neoadjuvant Therapy in Borderline Resectable Pancreatic Cancer\nEstimated
  primary completion: 31 December 2028. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/tak-921#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT07415525
URL:https://assetmemo.bio/drug/tak-921#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07483567-11359@assetmemo.bio
DTSTAMP:20261121T004110Z
DTSTART;VALUE=DATE:20300630
DTEND;VALUE=DATE:20300701
SUMMARY:TAK-921: Phase 2 readout est. (NCT07483567)
DESCRIPTION:TAK-921\, phase 2.\nStudy: IBI343 in Combination With Sintilima
 b and SOX Regimen for Perioperative Treatment of Resectable\, Locally Adva
 nced Gastric or Gastroesophageal Junction Adenocarcinoma\nEstimated primar
 y completion: 30 June 2030. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/tak-921#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT07483567
URL:https://assetmemo.bio/drug/tak-921#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
